• Circulating Tumor DNA (ctDNA) in Hematological Malignancy
  • Mohammad Zahedi,1,* Mohammad Ali Hamidinejad,2
    1. 1. Department of Medical Biotechnology, Student Research Committee, School of Allied Medical Science, Iran university of medical science
    2. Department of Medical Biotechnology, Student Research Committee, School of Allied Medical Science, Iran university of medical science


  • Introduction: Tissue and bone marrow biopsies and other invasive and unpleasant procedures remain the gold standard for cancer diagnosis and surveillance. These procedures involve physical risks, and a single biopsy cannot account for the spatial heterogeneity of tumors. This review discusses the current knowledge and landscape of liquid biopsy ctDNA in hematological malignancies.
  • Methods: This study performed by using collected article in English were available on details of the main topic since 2000 to 2022 in Scopus, PubMed, Web of Science with keyword ctDNA, liquid biopsy, hematological malignancy, cancer. Articles were selected on the basis of the exclusion criteria and after reviewing were included in the study.
  • Results: With breakthroughs in noninvasive cancer detection and monitoring, doctors, especially hematologists, have become increasingly acquainted with the term "liquid biopsy." the concentration of cfDNA in cancer patients is often greater than in healthy individuals, indicating that the amount of cfDNA could be utilized for cancer screening. Circular tumor DNA (ctDNA) analysis has advanced fast for cancer detection, characterization, and monitoring. Increasing clinical evidence demonstrates this technology's capabilities as a diagnostic test. The full potential of ctDNA liquid biopsy in the diagnosis, characterization, and management of solid and hematological malignancies will be found through clinical trials that test its effectiveness in the real world
  • Conclusion: Much research has shown that ctDNA could be used as a noninvasive biomarker for disease monitoring in the past few years. However, few published research supports the use of ctDNA in hematological malignancy. In conclusion, ctDNA surveillance may help detect hematologic cancer patients at risk of recurrence before established clinical criteria.
  • Keywords: ctDNA, liquid biopsy, hematological malignancy, cancer